Translational Nanoparticle Engineering for Cancer Vaccines

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2017 Nov 11

PMID 29123947

Citations 22

Authors

Adam J Grippin

Elias J Sayour

Duane A Mitchell

Affiliations

Soon will be listed here.

Abstract

Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors. Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.

Citing Articles

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.

Li H, Gong Y, Yan P, Xu Y, Qin G, Wen W Front Immunol. 2024; 15:1453753.

PMID: 39676875 PMC: 11638222. DOI: 10.3389/fimmu.2024.1453753.

Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.

Mariotti M, Giacon N, Lo Cascio E, Cacaci M, Picchietti S, Di Vito M Pharmaceutics. 2024; 16(9).

PMID: 39339254 PMC: 11434782. DOI: 10.3390/pharmaceutics16091218.

Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.

Deshmukh R, Sethi P, Singh B, Shiekmydeen J, Salave S, Patel R Pharmaceutics. 2024; 16(8).

PMID: 39204421 PMC: 11360117. DOI: 10.3390/pharmaceutics16081076.

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.

Zhao J, Liao B, Gong L, Yang H, Li S, Li Y Hum Vaccin Immunother. 2023; 19(2):2254262.

PMID: 37728107 PMC: 10512878. DOI: 10.1080/21645515.2023.2254262.

References

Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L . Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008; 29(3):497-510. PMC: 2688399. DOI: 10.1016/j.immuni.2008.07.013. View

Nicholaou T, Ebert L, Davis I, McArthur G, Jackson H, Dimopoulos N . Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009; 15(6):2166-73. DOI: 10.1158/1078-0432.CCR-08-2484. View

Shima F, Uto T, Akagi T, Baba M, Akashi M . Size effect of amphiphilic poly(γ-glutamic acid) nanoparticles on cellular uptake and maturation of dendritic cells in vivo. Acta Biomater. 2013; 9(11):8894-901. DOI: 10.1016/j.actbio.2013.06.010. View

Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S . Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano. 2014; 8(9):9209-18. DOI: 10.1021/nn502975r. View

Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y . Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2008; 123(10):2362-9. DOI: 10.1002/ijc.23810. View

Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E . High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine. 2014; 32(45):5901-7. DOI: 10.1016/j.vaccine.2014.09.002. View

Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A . Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer. 2007; 120(10):2178-84. DOI: 10.1002/ijc.22583. View

Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A . Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2003; 3(1):49-57. DOI: 10.3816/clc.2001.n.018. View

Mitchell D, Cui X, Schmittling R, Sanchez-Perez L, Snyder D, Congdon K . Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011; 118(11):3003-12. PMC: 3175779. DOI: 10.1182/blood-2011-02-334565. View

10.

Berinstein N, Karkada M, Oza A, Odunsi K, Villella J, Nemunaitis J . Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015; 4(8):e1026529. PMC: 4570133. DOI: 10.1080/2162402X.2015.1026529. View

11.

Mehta N, Wurz G, Burich R, Greenberg B, Griffey S, Gutierrez A . L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res. 2012; 18(10):2861-71. DOI: 10.1158/1078-0432.CCR-12-0168. View

12.

Fry T, Mackall C . Interleukin-7: from bench to clinic. Blood. 2002; 99(11):3892-904. DOI: 10.1182/blood.v99.11.3892. View

13.

Fukuda S, Pelus L . Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006; 5(5):1087-98. DOI: 10.1158/1535-7163.MCT-05-0375. View

14.

Silva J, Vandermeulen G, Oliveira V, Pinto S, Rodrigues C, Salgado A . Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach. Nanomedicine (Lond). 2014; 9(17):2639-56. DOI: 10.2217/nnm.14.135. View

15.

Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth A . Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2011; 130(3):584-92. DOI: 10.1002/ijc.26074. View

16.

Slingluff Jr C, Petroni G, Olson W, Smolkin M, Chianese-Bullock K, Mauldin I . A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunol Immunother. 2015; 65(1):25-36. PMC: 5010424. DOI: 10.1007/s00262-015-1770-9. View

17.

North S, Graham K, Bodnar D, Venner P . A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol. 2006; 176(1):91-5. DOI: 10.1016/S0022-5347(06)00494-0. View

18.

Soema P, Willems G, Jiskoot W, Amorij J, Kersten G . Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. Eur J Pharm Biopharm. 2015; 94:427-35. DOI: 10.1016/j.ejpb.2015.06.026. View

19.

Klein O, Davis I, McArthur G, Chen L, Haydon A, Parente P . Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. Cancer Immunol Immunother. 2015; 64(4):507-18. PMC: 11029160. DOI: 10.1007/s00262-015-1656-x. View

20.

Rossmann E, Osterborg A, Lofvenberg E, Choudhury A, Forssmann U, von Heydebreck A . Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study. Hum Vaccin Immunother. 2014; 10(11):3394-408. PMC: 4514088. DOI: 10.4161/hv.29918. View